AcuFocus Receives FDA Approval for the IC-8 Apthera IOL, the First and Only Small Aperture Lens
AcuFocus has received FDA approval for its IC-8 Apthera IOL, the first and only non-toric extended depth-of-focus IOL approved for the 82% of cataract patients who have as much as 1.5 diopters (D) of corneal astigmatism.2
“We are delighted to receive FDA approval for our first-of-its-kind Apthera IOL,” said Al Waterhouse, president and chief executive officer for AcuFocus. “The Apthera IOL represents several firsts for surgeons and patients: the first small aperture IOL to receive FDA approval, the first lens indicated for implantation with a monofocal or monofocal toric IOL in the fellow eye, the first extended depth of focus lens indicated for monovision, and the first non-toric IOL indicated for cataract patients with low amounts of corneal astigmatism.”
The Apthera IOL, with its proprietary small aperture technology, is designed to provide excellent distance vision as well as clear intermediate and near vision, effectively mitigating the effects of presbyopia.
“The Apthera IOL is the first lens design, with its embedded FilterRing component, to mitigate the effects of presbyopia by simply filtering out peripheral defocused and aberrated light that degrades image quality. This allows central focused light to be delivered to the retina,” Vance Thompson, MD, of Vance Thompson Vision, Sioux Falls, South Dakota, said in a company news release. “This novel mechanism of action provides patients with continuous range of vision from far through intermediate and near, even if they have as much as 1.5 D of corneal astigmatism.”
The FDA approval of the Apthera IOL is based on data from the U.S. Investigational Device Exemption study that evaluated the safety and effectiveness of the Apthera IOL implanted in one eye and a monofocal or monofocal toric IOL implanted in the fellow eye. A total of 453 subjects were enrolled and followed for 12 months. Outcomes for the Apthera IOL group (n=343) were compared to a control group (n=110) receiving a monofocal or monofocal toric IOL in both eyes. Apthera IOL treated eyes maintained 2 D of extended depth of focus and demonstrated 0.91 D of additional range of vision benefit over monofocal IOL eyes at 0.2 logMAR threshold, exceeding the 0.50 D ANSI criterion for extended depth of focus IOLs. Apthera IOL subjects achieved equivalent uncorrected distance vision and statistically superior intermediate and near vision compared to control subjects. Apthera IOL subjects also achieved comparable binocular contrast sensitivity to control subjects in both photopic and mesopic conditions, a first reported for an extended depth of focus lens.
“As one of the clinical investigators for the Apthera IOL, I saw firsthand how the unique optics work, and I can’t wait to add it to my practice,” said Elizabeth Yeu, MD, of Virginia Eye Consultants, Norfolk, Virginia. “The Apthera IOL is unlike any lens we have had before. I believe it will fill a significant gap in our IOL armamentarium allowing every cataract surgeon to meaningfully expand their treatment options for patients.”
The company plans to begin with a limited commercial release of the Apthera IOL in the US in the fall of 2022.
References:
1. National Eye Institute. https://www.nei.nih.gov/about/news-and-events/news/nei-charts-clearer-future-cataract-prevention-and-treatment. June 29, 2017.
2. Prevalence of Corneal Astigmatism Prior to Cataract Surgery. https://www.doctor-hill.com/physicians/docs/Astigmatism.pdf. Accessed July 18, 2022.
3. American Academy of Ophthalmology. https://www.aao.org/eye-health/diseases/what-is-astigmatism. July 18, 2022.